Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
PREVYMIS™ approved in Japan
Approval of MSD’s PREVYMIS™ (letermovir) in Japan triggers EUR 15 million milestone payment for AiCuris
- Approval allows MSD to market this innovative product in Japan
- AiCuris to receive next milestone payment of 15 million Euros, bringing the total amount of upfront and milestone payments received from MSD to 260 million Euros
AiCuris and Max Planck Institute
AiCuris and Max Planck Institute of Molecular Physiology join forces in the field of anti-infectives
AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of innovative drugs targeting infectious diseases and the Max Planck Institute of Molecular Physiology (MPI) in Dortmund, Germany, have entered into a collaborative agreement to identify novel compounds for the treatment of viral and bacterial infections.
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.